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To investigate the correlation between sensitivity to Fas ligand (FasL) and expression level of decoy receptor 3 
(DcR3) on tumor cell surface, Fas/DcR3 mRNA expression was detected by RT-PCR. Anti-DcR3 mAb was used to 
detect expression level of DcR3 on surface of tumor cells by flow cytometry. Caspase-8, caspase-9, caspase-3, Bcl-2 
expressions were analyzed by Western blot, respectively. Sensitivity to apoptosis induced by FasL was determined 
by Annexin V apoptosis kit. The expressions of DcR3 on the surface of tumor cells from high to low were 
approximately 35.3% in BGC823 cells, and 21.6% in MCF-7 cells, respectively. The apoptotic rates induced by 
FasL from low to high were 15.6% in BGC823 cells, and 58.2% in MCF-7 cells, respectively. There was a 
significant correlation between the expression levels of DcR3 with FasL-inducing apoptosis. Cellular & Molecular 
Immunology. 2007;4(6):455-460. 
 





Fas ligand (FasL), a type II membrane protein, belongs to the 
tumor necrosis factor (TNF) superfamily (1). FasL is 
expressed by activated T lymphocytes and natural killer (NK) 
cells, and by a small number of non-lymphoid cells (2). The 
expression of FasL has also been reported in non-immune 
cells, mainly from immune-privileged tissues such as testis, 
cornea, trophoblast, and cancer cells, which suggests that the 
Fas-FasL system may play an important role in the privileged 
status (3-5). The Fas (CD95) antigen, a 45-kDa protein of the 
TNF receptor (TNFR) family, is widely expressed and binds 
FasL (6). By engaging its receptor (Fas) membrane-bound 
FasL induces apoptosis in the target cell and, in this way, 
FasL plays a central role in both cell-mediated immunity and 
immune down-regulation (7). Hiroshi Arai, et al. reported 
that transfection of FasL gene into the CT26 colon carcinoma 
which did not express Fas inhibited its growth in vivo. These 
findings suggest that gene transfer of FasL generates 
apoptotic responses (8). 
Recent studies have suggested that resistance to apoptosis 
with loss of Fas function may play an important role in the 
pathogenesis of several malignancies (9). In addition, Decoy 
receptor 3 (DcR3) was recently reported, which is a decoy 
receptor for FasL. DcR3 lacks an apparent transmembrane 
sequence, may be a secreted, rather than a membrane- 
associated receptor. Pitti et al. (10) found that the DcR3 gene 
was amplified in approximately half of various human lung 
tumors and adenocarcinomas and suggested that over- 
expression of DcR3 receptor may exist in these tumors, 
meaning that the growth advantage of tumor cells was due to 
blockade of FasL-induced cell death (11). 
It has been reported that there are two kinds of FasL 
receptors, death receptors and decoy receptors. Fas can 
transfer death signal, resulting in cell apoptosis (12). DcR3 
doesn’t have death domain, so it couldn’t transfer death 
signal (13). In this study, we examined the effect of DcR3 
expression on tumor cell lines, finding the correlation 
between sensitivity to FasL inducing apoptosis in tumor cell 
lines and the expression of DcR3. 
 
Materials and Methods 
 
Cell culture 
Hela (cervical carcinoma cell), BGC823 (gastric carcinoma 
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cell), MGC803 (gastric carcinoma cell), MCF-7 (breast 
carcinoma cell), BEL7402 (hepatocellular carcinoma cell), 
H9101 (hepatocellular carcinoma cell), and HL60 (human 
promyelocytic leukemia cells) were routinely maintained at 
37oC in a humidified atmosphere of 5% CO2 and 95% air in 
RPMI 1640 medium supplemented with 10% fetal bovine 
serum (FBS) (Gibco BRL) and 2 mM glutamine.  
 
Expression and purification of recombinant human FasL in 
Escherichia coli  
The plasmid pET-22b(+)-FasL for the expression of rhFasL 
was constructed previously by over-lapping PCR in our 
laboratory. Plasmid DNA which contains a six-histidine tag 
was then transformed into the E. coli Rosetta-gami (Invitrogen). 
Further purification was carried out through a nickel ion 
column (Novagen, USA).  
 
Analysis DcR3 expression of tumor cell lines by flow cytometry 
All cells (1 × 105/ml) were incubated with anti-DcR3 mAb 
(100 μl/ml) (Sigma, USA) in 0.5% BSA in PBS for 30 min 
on ice. The cells were washed in cold PBS three times, 
followed by incubation with a fluorescent (FITC)-conjugated 
affinity-purified goat anti-rabbit IgG (Sigma, USA) for 30 
min on ice. After washed, the cells were analyzed by 
FACSCalibur flow cytometer (Becton Dickinson, USA). 
 
RT-PCR analysis for expression of Fas/DcR3 mRNA 
All cells treated with or without rhFasL (1 × 107/ml) were 
harvested by centrifugation. Total RNA (2 μg) was extracted 
using Trizol reagent from these cells, then RNA was 
reverse-transcribed with 20 U of reverse transcriptase using 
the Superscript TM II Kit (Gibco-BRL, USA) according to 
the manufacturer’s instructions. 
 
MTT analysis  
The effect of rhFasL on cell proliferation was measured using 
an MTT (Microtiter-tetrazolium, Sigma, USA) based assay. 
Briefly, the cells (5,000/ml) were incubated in triplicate in a 
96-well plate (Costar, Cambridge, MA, USA) in the presence 
of various concentrations of rhFasL (1.5625, 3.125, 6.25, 
12.5, 25, 50 μg/ml ) in a final volume of 0.2 ml for the 
indicated times. Thereafter, 20 μl of MTT solution (5 g/L) 
was added to each well and then incubated for 12 h. After 
centrifugation, the supernatant was removed from each well. 
The colored formazan crystal produced from MTT was 
dissolved in 0.15 ml of DMSO and then the optical density 
(OD) value was measured at 490 nm by a multiscanner 
autoreader (Dynatech MR 5000, Chantilly, VA, USA). The 
following formula was used: cell proliferation inhibited (%) 
= [1 - (OD of the experimental samples / OD of the control)] 
× 100%.  
 
Apoptosis assay by flow cytometry 
To determine the apoptosis, rhFasL treated or not treated cells 
(25 μg/ml, 1 h) were washed in PBS and resuspended in 
binding buffer at a concentration of 1 × 106 cells/L. After 
incubation, 195 μl of the solution was transferred to a 5 ml 
culture tube with 5 μl Annexin V-FITC (BD, USA) added. 
The tube was then incubated for 30 min at room temperature 
in the dark. The cells were washed with binding buffer and 
resuspended in 190 μl binding buffer, with 10 μl PI added. 
Finally, the tube was gently vortexed and incubated for 
another 30 min in the dark. Cells were analyzed by 
FACSCalibur with CellQuest software. 
 
DNA fragmentation  
DNA fragmentation served as a late apoptosis marker was 
detected by agarose gel electrophoresis. Cells (1 × 106 cells/ 
ml) at exponentially growing phase were treated with or 
without rhFasL (25 μg/ml) for 4 h. The cells were washed 
twice with cold PBS, pelleted by centrifugation and lysed in 
2 ml lysis buffer (50 mM Tris-HCl, pH 7.4; 10 mM EDTA 
and 0.5% sodium N-lauroylsarcosinate). Lysate was incubated 
sequentially with 500 mg/ml ribonuclease A at 50°C for 30 
min and 500 mg/ml proteinase K at 50°C for 60 min in a 
shaking water bath. Equivalent amounts of DNA (2-3 mg) 
were then analyzed by 2% agarose gel electrophoresis.  
 
Western blot 
Aliquots (30 μg of protein) of cell lysates were separated on 
12% SDS-PAGE, blotted onto a nylon membrane and probed 
with antibodies against Caspase-8, Caspase-3, Caspase-9 and 
Bcl-2 (Sigma, USA). Membranes were washed with 0.05% 
(vol/vol) Tween 20 in PBS (pH 7.6) and incubated with 1: 
2,000 dilution of horseradish peroxides-conjugated secondary 
Abs (Promega, USA) for 60 min at room temperature. 
Protein bands were visualized by DAB (3, 3’-Diamino- 
benzidine) reaction. 
 
Statistical analysis  
Data were presented as the mean ± SD per group. Statistical 
analysis was made for multiple comparisons using analysis of 
variance and Student t test. The p value < 0.05 was 




The rhFasL expression and purification 
The E. coli expression system was used to prepare rhFasL in 
inclusion form. After isolated and purified, the purity of the 
target protein was above 98%. On SDS-PAGE, the mobility 
of the purified protein was found to correspond to a 
molecular weight of 35 kDa (Figure 1). The purified protein 
was further examined by Western blot using anti-human 
FasL antibody. As shown in Figure 1, the rhFasL migrated at 
35 kDa as expected and no degradation was observed. 
 
Surface expression of DcR3 on different cell lines 
We examined the cell-surface expression of DcR3 on 
different cell lines by flow cytometry using the anti-DcR3 
mAb. As represented in Figure 2, approximately 35.3% of 
BGC823 cells, 31.9% of Hela cells, 28.8% of MGC803 cells, 
27.5% of BEL7402 cells, 24.9% of H9101 cells, 23.9% of 
HL60 cells, and 21.6% of MCF-7 cells expressed DcR3.  
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mRNA expression of Fas, DcR3 in tumor cell lines  
FasL induces apoptosis in tumor cell lines through its 
receptors. The levels of Fas and DcR3 mRNA expression in 
seven tumor cell lines were different. The expression of Fas 
mRNA exists in all cells with low levels before rhFasL 
treatment. After giving rhFasL at the concentration of 25 
μg/ml for 4 h, the levels of Fas mRNA expression in Hela, 
MGC803 and BEL7402 were decreased, while the expression 
of DcR3 mRNA increased. Under the same condition, the 
levels of Fas and DcR3 mRNA expression in MCF-7, H9101 
and HL60 were increased, while the extent of increase 
expression of DcR3 mRNA was lower than Fas mRNA 
(Figure 3).  
 
Correlation between apoptosis induced by rhFasL and 
expression level of DcR3 on tumor cell lines 
In order to study the relationship of rhFasL inducing tumor 
cell apoptosis and DcR3 expression, we firstly used MTT 
assay to determine the cell growth blocked by rhFasL. The 
sensitivities of tumor cell lines to rhFasL were different 
(Figure 4). Cell lines HL60, MCF-7, MGC803, BGC823 and 
H9101 were sensitive to rhFasL. Cell lines BEL7402 and 
Hela were partially sensitive to rhFasL in a dose dependent 
manner. Their IC50 values at 12 h were 12.3 ± 0.7 μg/ml of 
MGC803, 54.1 ± 1.1 μg/ml of BEL7402, and 6.4 ± 0.5 μg/ml 
of MCF-7, 22.3 ± 0.7 μg/ml of HL60, 6.1 ± 1.1 μg/ml of 
BGC823, and 26.4 ± 0.5 μg/ml of H9101, 64.1 ± 1.3 μg/ml 
of Hela.  
Genomic DNA fragmentation as a hallmark of apoptotic 
cell death was confirmed using an agarose gel electrophoresis. 
After treatment of cells with rhFasL, at 25 μg/ml for 4 h, a 
typical ladder pattern of internucleosomal DNA fragmenta- 
tion was observed comparing with control groups (Figure 5).  
We further analyzed the cell death mode induced by 
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Figure 1. Recombinant rhFasL protein purification and
identification. Purified rhFasL proteins were analyzed by SDS-
PAGE. Lane M, molecular weight markers; Lane 1, proteins were 
purified using a Nickel-affinity chromatography column; Lane 2, 
total insoluble protein; Lane 3, total soluble protein; Lane 4, 
proteins of colony induced with 0.3 mM IPTG; Lane 5, proteins of 
colony induced without IPTG; Lane 6, proteins of colony with 
plasmid pET-22b(+) induced with 0.5 mM IPTG; Lane 7, Western 
blot analysis of rhFasL protein using anti-human FasL antibody 




















Figure 2. Surface expression of DcR3 on tumor cell lines. The 
cells were incubated with anti-DcR3 mAb, and stained with 















Figure 3. mRNA levels of Fas and DcR3 were measured by RT-PCR. Total RNA was isolated from each sample and subjected to 
RT-PCR. The RT-PCR products were analyzed on 1.5% agarose gel electrophoresis. The results showed after rhFasL treatment, the level of 
Fas mRNA expression in Hela, MGC803 and BEL7402 were lower compared with control group, while the expression of DcR3 mRNA 
increased. With the same condition, the levels of Fas and DcR3 mRNA expression in MCF-7, H9101 and HL60 were increased. 
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H9101 and MCF-7 cell death mode mediated by FasL were 
mostly apoptosis, and BEL7402, MGC803 cells death mode 
mediated by FasL is mostly necrosis, while BGC823 and 
Hela cells were the secondary necrotic cells.  
Analysis of the expression of the proteins involved in the 
apoptosis pathway revealed that the expressions of Caspase-8, 
Caspase-3 and Caspase-9, Bcl-2 exist in all cell lines without 
rhFasL treatment. After treatment with rhFasL at 25 μg/ml 
for 4 h, the expressions of Caspase-8, Caspase-3 and 
Caspase-9 in HL60, H9101 and MCF-7 cells were up- 
regulated compared with control group and their proteolytic 
fragments were detected (data not shown). While the 
expression of Bcl-2 in the same cells decreased obviously. 
Before and after giving rhFasL, the expressions of Caspase-8, 
Caspase-3 and Caspase-9, Bcl-2 in other tumor cell lines 
were not distinctly different (Figure 7). 
At last, we used statistical methods to study the 
correlation between apoptosis induced by FasL and 
expression levels of DcR3 on the surface of tumor cells. The 
results suggested that the expression levels of DcR3 on 
surface of tumor cells were relevant to the sensitivity to FasL 






























Figure 4. Cytotoxic effects of rhFasL on tumor cell lines. Tumor 
cell lines (HL60, MCF-7, BGC823, MGC803, BEL7402, Hela and
H9101) were treated with rhFasL for 12 h at the indicated 
concentrations. The results showed that cell lines HL60, MCF-7, 
MGC803, BGC823 and H9101 were sensitive to rhFasL. Cell lines 
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Figure 5. DNA fragmentation was observed undergoing rhFasL-
induced apoptosis by agarose gel electrophoresis. Cells treated
with 25 μg/ml rhFasL for 4 h. Lane 1, tumor cells without any 
treatment; Lane 2, Hela treated with rhFasL; Lane 3, MCF-7 treated
with rhFasL; Lane 4, MGC803 treated with rhFasL; Lane 5, 
BGC823 treated with rhFasL; Lane 6, BEL7402 treated with

































Figure 6. Cell death mode analysis of tumor cells treated with or without rhFasL by flow cytometry. Tumor cells were treated with or 
without rhFasL (25 μg/ml) for 1 h, and stained with Annexin V and PI. Then the cells were analyzed by FACS. 
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regulator of programmed cell death (14). Stimulation of the 
Fas receptor by FasL or agonist antibody results in the rapid 
induction of apoptosis which is dependent upon a signal 
transduction cascade involving the caspase family of 
proteases and is independent of new RNA or protein 
synthesis (15, 16). Apoptosis induced by the Fas receptor is 
characterized by cell shrinkage, plasma membrane blebbing, 
and DNA fragmentation into nucleosomal sized fragments. 
Fas-/FasL+ and FasL-mRNA+ HCC cells were detected in 
the specimen of moderately-differentiated cells (17), suggested 
that Fas/FasL expression was decreased in proportion to the 
malignancy of tumor cells. Furthermore, the apoptosis in 
HCC could be regulated by the suppression of Fas/FasL 
expression, or sometimes, by the enhancement of FasL 
expression.  
Our studies demonstrated that the apoptosis of tumor cell 
lines were relevant to DcR3 and Fas mRNA expression. The 
different mRNA expressions of DcR3 and Fas may be the 
key point of selectively induction apoptosis of FasL (18, 19). 
We examined the anti-proliferation activity of rhFasL 
against tumor cell lines. Interestingly, their anti-proliferation 
effect was gradually augmented with the increased rhFasL 
concentration. When the cell lines which have higher DcR3 
expression, the anti-proliferation activity of rhFasL was lower. 
These results suggested that the activity may be due to the 
DcR3 expression on tumor cells. 
DNA fragmentation occurs in cell apoptosis induced by a 
variety of agents. This cleavage produces ladders of DNA 
fragments in the size of integer multiples of a nuclesome 
length (180-200 bp) (20). Due to their characteristic patterns 
revealed by agarose gel electrophoresis, these nucleosomal 
DNA ladders are widely used as biochemical markers of 
apoptosis. A characteristic ultra-structural appearance of 
apoptotic cells is observed under an electron microscope (data 
not shown). 
Information summarized above is consistent with the 
results of cell death mode assessed by Annexin V staining. 
When the cell lines had higher DcR3 expression, their 
apoptotic rate induced by rhFasL was lower. 
It is clear that caspase family members play important 
roles in driving apoptosis. Activation of caspase appears to be 
directly responsible for many of the molecular and structural 
changes in apoptosis (21). In this study, increased expression 
of Caspase-3 was observed directly in HL60, H9101 and 
MCF-7 cells after treatment with rhFasL. Distinct activation 
of Caspase-3, demonstrated by the appearance of proteolytic 
fragment, was detected 4 hours after FasL treatment. 
Over-expression of Caspase-8 and Caspase-9 resulting in 
apoptosis has been reported. The data presented here showed 
that Caspase-8 and Caspase-9 were up-regulated and 
cleavage of Caspase-8 was detected in HL60, H9101 and 
MCF-7 cells (data not shown). Our observations suggested 
that rhFasL induced apoptosis in tumor cell lines through 
up-regulation of Caspase-8, Caspase-9 and Caspase-3 
activation. Our additional experiments showed that rhFasL 
could down-regulate the expression of Bcl-2 protein in HL60, 



















Figure 8. Analysis of the correlation between apoptosis induced 
by FasL and expression levels of DcR3 on surface of HL60, 
MCF-7, BGC823, MGC803, BEL7402, Hela, H9101 cells. For 
calculating cell apoptosis rate, the cells were treated with FasL for 1
h at 25 μg/ml, and then were measured by flow cytometry after 
staining by Annexin V/PI. For calculating DcR3 expression rate, the 
cells added with anti-DcR3 mAb, and detected by flow colometry
after staining by FITC.  
FasL - +
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Figure 7. Protein level detection of Caspase-8, Caspase-3, Caspase-9 and Bcl-2 in tumor cell lines by Western blot analysis. Aliquots 
of cell lysates were separated on SDS-PAGE, blotted onto a nylon membrane and probed with antibodies against Caspase-8, 
Caspase-3, Caspase-9 and Bcl-2. The HRP-conjugated anti-goat antibody was used as secondary antibody. The results showed that the 
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cell lines have higher DcR3 expression, their Caspase-8, 
Caspase-9 and Caspase-3 expressions were lower and Bcl-2 
expressions were higher after rhFasL treatment. 
In conclusion, our studies suggested that the sensitivity of 
tumor cells to rhFasL should be relevant to the DcR3 
expression, and the mRNA expressions of its receptors and 
the release of Caspase-8, Caspase-9, Caspase-3, and Bcl-2. 
Further studies of its molecular mechanism involved are 
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